ClinicalTrials.gg
Status unknownNCT04571879Updated Mar 2, 2023

Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children

A Phase 3 interventional study of Nebulized Lidocaine and Intranasal Midazolam in Procedural Anxiety and Procedural Pain, sponsored by Hamad Medical Corporation. Status unknown at 2 sites in Qatar. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Hamad Medical Corporation · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing lidocaine in Pain, Procedural — 1 open to participants now, 1 under way, none of them phase 3. Lidocaine · Pain, Procedural.

Planned enrollment
11th of 11
48 · median 180
Started
2021
the only one that year
Phase 3
6 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Hamad Medical Corporation

Among the 11 studies testing lidocaine in Pain, Procedural, this one is the 11th largest by planned enrollment, is the only one that started in 2021, is one of 6 in phase 3, and was the 6th registered.

Pain, Procedural

243 studies on the registry are indexed under Pain, Procedural; 66 are open to participants now.

Browse Pain, Procedural studies →

Open to participants now

1 of the 11 studies testing lidocaine in Pain, Procedural is open now. Recruiting first, the newest first:

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 29 Pain, Procedural studies recruiting now, 13 (45%) set no upper age limit and 14 (48%) stop at 75 or younger; 14 take children under 18; 5 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing lidocaine in Pain, Procedural, or all of them as a file.
02

Study summary

Nasogastric tube (NGT) is a commonly performed procedure in the Emergency Department. Although it is not a major procedure, it is usually associated with a bad experience and cause discomfort and pain in kids. This randomized controlled double-blinded double-dummy trial aims to investigate the efficacy of local topical anesthetic and/or anxiolysis for pain/anxiety related to NGT insertion. Eligible patients are children with gastroenteritis aged 6 months to 5 years requiring NGT rehydration. The intervention are 3 arms of nebulized lidocaine with midazolam compared to nebulized midazolam alone or placebo. The primary outcome is procedure-related pain assessment using the Face, Legs, Activity, Cry, and Consolability (FLACC) scale during final NGT insertion attempt.

Read the detailed description

Nasogastric tube (NGT) insertion is commonly performed in the emergency department (ED) which can cause some pain/anxiety [Shih S and Rosen P, 2018]. The pain/discomfort related to NGT insertion comes from anxiety, gagging and sensitivity of nasopharynx and oropharynx [Tapiawala SN et al, 2008]. Success rate depends on cooperation, which limits order for nasogastric tube insertion in most patients especially in non-pediatric hospitals.

The pain and anxiety associated with such procedures in kids is a source of noxious stimuli to the nervous system. Not only does pain have a negative impact on neurological development, but children whose pain has not been adequately treated in infancy or early childhood reported lower pain thresholds as adolescents and adults [Ruda M.A.et al, 2000]. If not addressed, this pain can lead to distress for children, their parents and those performing the procedures, preprocedural anxiety in the future and can result in negative long-term emotional outcomes [Blount R.L et al,2006; Brewer S.G. et al, 2006].

Nebulized 2% lidocaine at doses of 4 and 8 mg/kg has shown to be safe in infants and children, with all blood levels obtained were well below the toxic range [Gjonaj S et al, 1997]. Nebulized lidocaine in doses up to 8 mg/kg appears to be safe and gave statistically significant reduction in pain score when used before flexible bronchoscopy [Gjonaj S et al, 1997]. Nebulized/intranasal lidocaine did not seem to be of benefit when used alone in the two previous trials for NGT insertion in children [Babl FE et al,2009; Craig SS et al, 2019]. On the other hand it greatly reduced discomfort associated with NG tube in adult population [Cullen L et al, 2004]. This might be explained by the anxiety and lack of cooperation, especially in young kids, which might limit the validity of pain score during the whole procedure.

Midazolam has a controlled sedation with a quicker recovery time. The safety and tolerability profile of midazolam in pediatric patients is comparable/superior to that observed in adults [Pacifici GM, 2014]. Midazolam is a GABA receptor agonist providing anxiolysis for procedures in pediatric population. Midazolam has been shown to be safe and effective for use in children [Wilton NC et al,1988; Theroux MC et al, 1993]. Intranasal midazolam has shown improvements with anxiety and crying, as well as need for restraint [Theroux MC et al, 1993]. Midazolam anxiolysis has been tried in pediatrics and ordered as nebulization, found to have a plasma concentration bioavailability which is comparable to the intranasal midazolam by the ratio (nebulized:nasal) of 1:2.9. [McCormick AS et al, 2008]. Clinically effective serum concentrations of intranasal midazolam can be reached within less than 10 min after nasal application [Knoester PD et al, 2002].

Lidocaine / Midazolam has been commonly used in different procedures in pediatric emergency department; such as urethral catheterization, intravenous cannulation, lumbar puncture with a great safety margin.

03

Conditions studied

  • Procedural Anxiety
  • Procedural Pain

Browse trials for

04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1 Previously healthy children 6 months to 5 years old presenting with AGE and some dehydration who were planned to have a nasogastric tube inserted as part of their ED treatment.

Exclusion criteria

Exclusion Criteria:

  1. Indication for an urgent insertion of a nasogastric tube.
  2. Congenital anomalies of nose, nasopharynx, oropharynx, or oral cavity.
  3. .Patients allergic to midazolam or lidocaine.
  4. .Congenital Heart disease or arrhythmia.
  5. .Known hepatic or renal impairment
  6. .Developmentally abnormal children
  7. .Patients with seizure disorder
  8. .Pre-existing abnormal neurological conditions
  9. .Child is taking medications known to interact with lidocaine and/or midazolam (antiarrhythmic drugs, suxamethonium, phenytoin, antidepressants, propranolol, citicoline).
  10. .Known case of severe gastroesophageal reflux disease or aspiration pneumonia.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr. Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg).

    Drug: Nebulized Lidocaine · Drug: Intranasal Midazolam

  • Experimental
    Arm 2

    Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg). Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr.

    Drug: Intranasal Midazolam

  • Placebo comparator
    Arm 3

    Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr.

    Other: Placebo

Interventions

  • Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children

    Also known as: Nebulized Xylocaine

  • Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion

    Also known as: IN Midazolam

  • OtherPlacebo

    Nebulized normal saline and intranasal normal sline

06

What researchers measure

Primary outcomes

  1. Pain severity rating scale (FLACC) during insertion of NGT.

    score from 0 to 10. Higher scores mean worse outcome

    Time frame: 1 year

Secondary outcomes

  1. Observer/caregiver pain severity rating:

    Score from 1 to 100. Higher scores mean worse outcome

    Time frame: 1 year

  2. The ease of procedure: difficulty of insertion on an ordinal scale from 1 to 5, where 5 is the most difficult insertion.

    Score from 1 to 5. Higher scores mean worse outcome

    Time frame: 1 year

  3. The number of attempts required to successfully insert the NGT

    The number of attempts of successful NGT insertion

    Time frame: 1 year

  4. Procedural complications/adverse events.

    Records complications and adverse effects

    Time frame: 1 year

  5. FLAC score at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and 180 minutes post insertion.

    Scores from 0 to 10. Higher scores mean worse outcome

    Time frame: up to 180 minutes

  6. Length of stay in ED

    Length of stay in minutes

    Time frame: up to 180 minutes

  7. Duration of NGT feed.

    The observer records data on chart

    Time frame: up to 180 minutes

  8. Tolerated volume of NGT feed.

    Amount of fluid (ml)

    Time frame: 1 year

07

Study locations

1 of 2 sites recruiting
  • Pediatric Emergency Center, Hamad Medical Corporation
    Doha, 3050, Qatar
    Recruiting
    • Fatihi Toaimah · Contact
  • Sidra Medicine
    Doha, 3050, Qatar
    Not yet recruiting
    • Khalid Alansari, MD · Contact
08

References and documents

Publications

  • Shih S, Rosen P. Pain Management for Nasogastric Intubation in Pediatrics. Cureus. 2018 Oct 9;10(10):e3429. doi: 10.7759/cureus.3429. PubMed 30555754 ↗
  • Tapaiwala SN, Al Riyami D, Cole E. A painful and knotted nasogastric tube. CMAJ. 2008 Feb 26;178(5):568. doi: 10.1503/cmaj.070750. No abstract available. PubMed 18299545 ↗
  • Ruda MA, Ling QD, Hohmann AG, Peng YB, Tachibana T. Altered nociceptive neuronal circuits after neonatal peripheral inflammation. Science. 2000 Jul 28;289(5479):628-31. doi: 10.1126/science.289.5479.628. PubMed 10915627 ↗
  • Blount RL, Piira T, Cohen LL, Cheng PS. Pediatric procedural pain. Behav Modif. 2006 Jan;30(1):24-49. doi: 10.1177/0145445505282438. PubMed 16330518 ↗
  • Brewer S, Gleditsch SL, Syblik D, Tietjens ME, Vacik HW. Pediatric anxiety: child life intervention in day surgery. J Pediatr Nurs. 2006 Feb;21(1):13-22. doi: 10.1016/j.pedn.2005.06.004. PubMed 16428010 ↗
  • Gjonaj ST, Lowenthal DB, Dozor AJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. Chest. 1997 Dec;112(6):1665-9. doi: 10.1378/chest.112.6.1665. PubMed 9404766 ↗
  • Babl FE, Goldfinch C, Mandrawa C, Crellin D, O'Sullivan R, Donath S. Does nebulized lidocaine reduce the pain and distress of nasogastric tube insertion in young children? A randomized, double-blind, placebo-controlled trial. Pediatrics. 2009 Jun;123(6):1548-55. doi: 10.1542/peds.2008-1897. PubMed 19482767 ↗
  • Craig SS, Seith RW, Cheek JA, Wilson K, Egerton-Warburton D, Paul E, West A. Lidocaine and phenylephrine versus saline placebo nasal spray for the pain and distress of nasogastric tube insertion in young children and infants: a randomised, double-blind, controlled trial. Lancet Child Adolesc Health. 2019 Jun;3(6):391-397. doi: 10.1016/S2352-4642(19)30058-6. Epub 2019 Apr 15. PubMed 31000379 ↗
  • Cullen L, Taylor D, Taylor S, Chu K. Nebulized lidocaine decreases the discomfort of nasogastric tube insertion: a randomized, double-blind trial. Ann Emerg Med. 2004 Aug;44(2):131-7. doi: 10.1016/j.annemergmed.2004.03.033. PubMed 15278085 ↗
  • Pacifici GM. Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. Int J Pediatr. 2014;2014:309342. doi: 10.1155/2014/309342. Epub 2014 Feb 18. PubMed 24696691 ↗
  • Wilton NC, Leigh J, Rosen DR, Pandit UA. Preanesthetic sedation of preschool children using intranasal midazolam. Anesthesiology. 1988 Dec;69(6):972-5. doi: 10.1097/00000542-198812000-00032. No abstract available. PubMed 3195771 ↗
  • Theroux MC, West DW, Corddry DH, Hyde PM, Bachrach SJ, Cronan KM, Kettrick RG. Efficacy of intranasal midazolam in facilitating suturing of lacerations in preschool children in the emergency department. Pediatrics. 1993 Mar;91(3):624-7. PubMed 8441570 ↗
  • McCormick AS, Thomas VL, Berry D, Thomas PW. Plasma concentrations and sedation scores after nebulized and intranasal midazolam in healthy volunteers. Br J Anaesth. 2008 May;100(5):631-6. doi: 10.1093/bja/aen072. Epub 2008 Apr 2. PubMed 18385262 ↗
  • Knoester PD, Jonker DM, Van Der Hoeven RT, Vermeij TA, Edelbroek PM, Brekelmans GJ, de Haan GJ. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002 May;53(5):501-7. doi: 10.1046/j.1365-2125.2002.01588.x. PubMed 11994056 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Dec 2023, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2020
First posted
Oct 1, 2020
StartActual
Aug 25, 2021
Primary completionEst.
Dec 30, 2023
CompletionEst.
Feb 28, 2024
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04571879
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Aug 25, 2021
Primary completion
Dec 30, 2023 (estimated)
Completion
Feb 28, 2024 (estimated)
Last update
Mar 2, 2023

Study contacts

Fatihi HS Toaimah, PhD
Contact
ftoaimah@hamad.qa
+97455628632
Khalid Alansari
Contact
kalansari@sidra.org
Fatihi Toaimah, MD, PhD
principal investigator · Hamad Medical Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Midazolam

Start the discussion